Non-Hodgkin Lymphoma

Craig B. Reeder, MD, assistant professor of Medicine, Mayo Clinic, discusses some future treatment approaches for patients with aggressive lymphomas, including diffuse large B-cell lymphoma.

At 29 months’ follow-up, frontline ibrutinib reduced the risk of of progression or death by 88% versus chlorambucil in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, according to the latest findings from the phase III RESONATE-2 trial.

Darrin M. Beaupre, MD, head of Early Development and Immunotherapy at Pharmacyclics, discusses a trial exploring the efficacy of ibrutinib in patients with marginal zone lymphoma.

Allison C. Rosenthal, DO, hematology consultant, Mayo Clinic, discusses the FDA approval of of ibrutinib (Imbruvica) as a treatment for patients with marginal zone lymphoma (MZL).

The FDA has granted an accelerated approval to ibrutinib as a treatment for patients who require systemic therapy with marginal zone lymphoma following at least one prior anti-CD20-based therapy, based on findings from a single-arm phase II study.

Danelle James, MD, discusses the updated RESONATE-2 data presented at the ASH Annual Meeting and the next steps with ibrutinib in CLL.

The fields of mantle cell lymphoma and diffuse large B-cell lymphoma had a handful of updates presented during the 2016 ASH Annual Meeting.